Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...
Two withdrawals of recently submitted initial public offering (IPO) filings by drug developers, plus a dearth of new filings this month, suggest that the outlook for biopharma IPOs remains cloudy, ...
Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...
Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL) in a phase 3 trial, setting up regulatory filings for ...
Boston College will begin recruiting the first class for its highly anticipated Human-Centered Engineering program, a major that will integrate BC’s core liberal arts focus and a rigorous engineering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results